Viking Therapeutics Announces Completion of Enrollment in Phase 2 VENTURE-Oral Dosing Trial of VK2735 Tablet Formulation in Patients with Obesity ...Middle East

13-Week Study Evaluating the Safety and Efficacy of Oral VK2735 Dosed Once Daily Results Expected in 2H25 SAN DIEGO, March 26, 2025 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies...

Read More Details
Finally We wish PressBee provided you with enough information of ( Viking Therapeutics Announces Completion of Enrollment in Phase 2 VENTURE-Oral Dosing Trial of VK2735 Tablet Formulation in Patients with Obesity )

Also on site :

• Apple claims San Jose engineer stole trade secrets, took them to rival
• Oil tanker explodes off Libyan coast after calling at Russian ports – Bloomberg
• Kendall Jenner’s Venice Getaway Post Draws Sweet Message from Kris Jenner